We look forward to working with Abbott to meet the needs of these patients in Japan. In 2009 2009, Abbott and Sucampo Japan Co. Ltd. Entered into a license, supply and commercialization contract for AMITIZA in Japan.. Abbott, Sucampo receive Japanese approval for AMITIZA Sucampo Pharmaceuticals, Inc. and Abbott today announced that Sucampo Pharma, Ltd. Related StoriesScripps Florida scientists earn $2.4 million to expand development of new suffering therapies We are very pleased to receive Japan’s first-ever approval for a prescription drugs for chronic constipation since it helps us achieve our objective of bringing medications with novel mechanisms of actions to individuals with unmet medical requirements on a worldwide basis, said Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo’s Chairman and CEO.‘The AOAC’s approval further validates our check as a great tool to egg makers, as they comply with the FDA’s new rules, and seek to further reduce the likelihood of SE-contaminated eggs reaching consumers,’ said Ed Bradley, Neogen’s vice president of Food Safety. ‘Until our launch of a highly effective rapid test for SE, the industry had to wait up to seven days for an outside laboratory’s test outcomes. Neogen, in cooperation with USDA researchers, began the advancement of this test in 2000. ‘Utilizing a rapid check for SE that uses the same sample enrichment process as the FDA not merely enables analysts to quickly screen out negative test results, but also is compatible with the FDA confirmation process utilizing the same enriched samples,’ stated Bradley.